The contrasting lack of prognostic effect for S-CTLA-4 in ADC patients may illustrate existing differences in the balance between activated immune cells with immunosuppressive and anti-tumor immune properties between histological NSCLC subgroups. This evidence concerns the gene CTLA4 and neoplasm.